Cancer Diagnostics Company - Pre-IPO Existing Shareholding - FDA Listed ISO13485 Certified
| Categories: | Securities, Pre-IPO / Grey Market |
| Sale Type: | Asking Price |
| Price Guide: | AUD 6M shares @ $0.14 per share (cum rights) = 24.32% discount to December 2016 Pre-IPO Rights Issue |
| Status: | Closed |
Summary:
Sale of pre-IPO existing shares by a motivated Seller in a public, unlisted Company based in Melbourne, Australia. Since 2007, the Company has successfully realised IP value in telomerase-based diagnostics to effectively identify bladder cancer. In 2016 it transitioned from a purely R&D company to a commercial entity with product revenues. Has recently formalised distribution agreements for US and UK markets. Since inception, the Company has raised A$16.1M in equity to successfully achieve milestones and has been well supported by considerable R&D Incentives.
Share this Listing
Arbortech
BlackWall
Blooms the Chemist
Federation Alternative Investments
Genex Power
Haoma Mining
Moneytech
Planet Innovation Holdings
PrimaryMarkets
VGW Holdings
Waratah Hotel Group
XYZ Ltd
Capital Raises
Investor Centres
Secondary Trading